G Life Awarded Deeptech Recognition for Its Innovative Research

G Life has obtained Deeptech recognition by Bpi France, highlighting the scientific and technological ambition of its Quantum Biomodulation approach.

Its research strategy is structured around three complementary programs: understanding the interactions between light and biological tissues, investigating the effects of photobiomodulation on tissue development and regeneration, and exploring its mechanisms of action on different cell types under stress conditions.

Together, these programs aim to deepen the scientific understanding of light-based biological modulation and support the development of future medical applications.

The program relies on scientific and academic collaborations involving EPFL, LAPP/CNRS-IN2P3, Aix-Marseille University, University of Geneva (Switzerland), and the Geneva School of Landscape, Engineering and Architecture (HEPIA, Switzerland).

January - 2025

At the Heart of the Cluster Lumière Event in Lyon

Our company had the pleasure of actively participating in the events organized by Cluster Lumière in Lyon in 2025, where our teams and founder, Dr. Sébastien Gerelli, shared our latest scientific advances through oral presentations. As an active member of Cluster Lumière’s scientific committee, these engaging exchanges allowed us to connect with key industry leaders and reaffirm our dynamic role within this ecosystem of excellence. We extend our sincere thanks to the organizers and participants for the high quality of discussions throughout the event. Moving forward, we enthusiastically continue these collaborations to put light and innovation at the service of health and future technologies.

September - 2025

New International Patent Application Filed for Tissue Cell Treatment Technology

Our company is proud to announce the filing of a new international PCT patent application for our invention entitled "DISPOSITIF ET MÉTHODE POUR LE TRAITEMENT DE CELLULES DES TISSUS PAR APPORT DE QUANTA D’ÉNERGIE SPÉCIFIQUES" (Device and method for treating tissue cells by delivering specific energy quanta). Filed via WIPO under reference PCT/IB2024/052594, this breakthrough technology relies on precise energy quanta delivery to optimize cellular treatment and biological response. This new milestone significantly expands our global intellectual property rights and reinforces our commitment to technological innovation in health sciences.

September - 2025

G Life Advances Cardiac Research with a PhD Student Élodie Payet

G Life is strengthening its research activities through the work of Élodie Payet, a PhD student involved in a collaborative research program with the University of Strasbourg.

Her research focuses on the potential of photobiomodulation to improve mitochondrial function and protect cardiac tissue.

This collaboration supports G·Life's ambition to advance the scientific foundations of innovative therapies in cardiovascular medicine.

November - 2025

Patent Granted for Innovative Photobiomodulation Device and Method

Our company is pleased to announce the grant of a new patent for our invention entitled "DEVICE AND METHOD FOR APPLYING PHOTOBIOMODULATION". This innovation relies on an advanced photobiomodulation (PBM) device and method capable of delivering optical power precisely tailored to the target biological optical properties and illumination geometry. By applying specifically calibrated fluence rates and exposure durations, our technology optimizes biological responses while enabling optional real-time metabolic activity monitoring. This major milestone strengthens our intellectual property portfolio and confirms our dedication to pioneering medical technologies.

December - 2025

G Life Strengthens Its Clinical Expertise with Dr. Caroline Fritz

G Life is pleased to announce a collaboration with Dr. Caroline Fritz, MD, PhD, as Medical & Scientific Advisor in Anesthesiology and Critical Care Medicine.

Drawing on her expertise in intensive care and clinical research, she will support the scientific development of G·Life's clinical programs, particularly in acute and critical care, including the review of study protocols and medical recommendations.

This collaboration reinforces G·Life's clinical expertise as it advances the development of its Quantum Biomodulation technology.

March - 2026

At the Heart of Cluster Lumière 2026 in Lyon

Our company had the pleasure of actively participating in the Cluster Lumière 2026 event in Lyon, where our founder Dr. Sébastien Gerelli and our teams presented our latest advances and research posters on PBM medical applications. As an active member of Cluster Lumière’s scientific committee, this event allowed us to engage with key industry leaders and reaffirm our role in this ecosystem of excellence. We extend our warmest thanks to the organizers and look forward to continuing our collaborations to put light and innovation at the service of health.

June - 2026

G Life Expands Its R&D Team with Silvia Calzuola

G Life is pleased to welcome Silvia Tea Calzuola as an R&D Engineer specializing in Microfluidics and Organoids.

She will contribute to the development of advanced microphysiological models, 3D cell cultures and microfluidic systems, supporting G·Life's scientific and Deeptech research programs.

Her arrival strengthens the company's experimental research capabilities and its commitment to developing innovative medical technologies.

September - 2026

Bpifrance Supports G Life's Deeptech Research Ambitions

G Life has secured Bpifrance's support for its Deeptech research and development programme. This important milestone will help accelerate the company's research activities, strengthen its scientific collaborations and advance the development of innovative medical technologies based on quantum biomodulation.

September 2026

G Life invests €2.3 Million R&D Programme to Advance Its Deeptech Research

G Life is pursuing a €2.3 million research and development programme as part of its Deeptech initiative, in collaboration with its scientific and technological partners. The programme aims to advance research into quantum biomodulation and support the development of innovative medical technologies. This R&D investment reflects G Life's commitment to advancing its scientific research and technological development.

October 2026

VITA: Art Meets Medicine in Fribourg

Our company is proud to announce its participation in "VITA," an artistic and scientific project featuring an immersive installation by visual artist Camille von Deschwanden, running in Fribourg from December 3 to 16, 2026. At the heart of this poetic experience, located at the foot of Fribourg Cathedral, are the research works on intramyocardial photonic regeneration led by our founder, Dr. Sébastien Gerelli. Through video projections of cardiac interventions and a 6-meter fiber-optic structure synchronized with music, medical precision and our technological innovations are transformed into a fascinating aesthetic work. This commitment fully illustrates our ongoing dedication to placing science and innovation at the service of life and the general public.

Coming Soon - December 2026